The latest on CAR-T cell therapy in China — approvals, international patient journeys, and the science of living drugs.
How an international patient with refractory diffuse large B-cell lymphoma reached a CAR-T program in China after multiple relapses.
Read story →From the first NMPA-approved CAR-T in 2021 to a fast-expanding pipeline — what international patients can access today.
Read article →Why solid tumors are harder for CAR-T — and how targets like Claudin18.2 and GPC3 are opening new fronts.
Read article →